| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1000638950 |
| P356 | DOI | 10.1038/SJ.ONC.1200873 |
| P698 | PubMed publication ID | 9038376 |
| P5875 | ResearchGate publication ID | 14173191 |
| P50 | author | Mark A. Lemmon | Q24076870 |
| P2093 | author name string | Stern DF | |
| Engelman DM | |||
| Burke CL | |||
| Coren BA | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | transmembrane protein | Q424204 |
| P304 | page(s) | 687-696 | |
| P577 | publication date | 1997-02-01 | |
| P1433 | published in | Oncogene | Q1568657 |
| P1476 | title | Dimerization of the p185neu transmembrane domain is necessary but not sufficient for transformation | |
| P478 | volume | 14 |
| Q40256858 | A constitutively active ERBB4/HER4 allele with enhanced transcriptional coactivation and cell-killing activities |
| Q40387199 | A new class of fusion-associated small transmembrane (FAST) proteins encoded by the non-enveloped fusogenic reoviruses |
| Q35596167 | A point mutation in the extracellular domain of KIT promotes tumorigenesis of mast cells via ligand-independent auto-dimerization |
| Q30476898 | A putative molecular-activation switch in the transmembrane domain of erbB2. |
| Q27681167 | A single ligand is sufficient to activate EGFR dimers |
| Q24310296 | ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma |
| Q90371029 | Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies |
| Q93198405 | Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations |
| Q33778555 | Activation of Neu (ErbB-2) mediated by disulfide bond-induced dimerization reveals a receptor tyrosine kinase dimer interface |
| Q34753802 | Activation of signaling receptors: do ligands bind to receptor monomer, dimer, or both? |
| Q33891072 | Activation of the erythropoietin receptor by the gp55-P viral envelope protein is determined by a single amino acid in its transmembrane domain |
| Q38634706 | Chemical synthesis of transmembrane peptide and its application for research on the transmembrane-juxtamembrane region of membrane protein |
| Q40959219 | Constitutively active MuSK is clustered in the absence of agrin and induces ectopic postsynaptic-like membranes in skeletal muscle fibers. |
| Q47718793 | Constitutively tyrosine phosphorylated p52 Shc in breast cancer cells: correlation with ErbB2 and p66 Shc expression |
| Q28679173 | Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers |
| Q43743809 | Dimer interface of transmembrane domains for neu/erbB-2 receptor dimerization and transforming activation: a model revealed by molecular dynamics simulations |
| Q39686854 | Early response to ErbB2 over-expression in polarized Caco-2 cells involves partial segregation from ErbB3 by relocalization to the apical surface and initiation of survival signaling |
| Q35749374 | HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks |
| Q34130541 | HER2/neu: mechanisms of dimerization/oligomerization |
| Q34171355 | Helix packing in polytopic membrane proteins: role of glycine in transmembrane helix association |
| Q33716113 | Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors |
| Q34103621 | Ligand discrimination by ErbB receptors: differential signaling through differential phosphorylation site usage |
| Q36254464 | Ligand-dependent responses of the ErbB signaling network: experimental and modeling analyses |
| Q39616171 | Ligand-independent dimer formation of epidermal growth factor receptor (EGFR) is a step separable from ligand-induced EGFR signaling |
| Q64008501 | Ligand-independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domain |
| Q24309071 | Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment |
| Q74460405 | Molecular dynamics simulations of the ErbB-2 transmembrane domain within an explicit membrane environment: comparison with vacuum simulations |
| Q44574016 | Molecular dynamics simulations of the transmembrane domain of the oncogenic ErbB2 receptor dimer in a DMPC bilayer. |
| Q34698008 | Muc4-ErbB2 complex formation and signaling in polarized CACO-2 epithelial cells indicate that Muc4 acts as an unorthodox ligand for ErbB2 |
| Q36824808 | Mutational activation of ErbB family receptor tyrosine kinases: insights into mechanisms of signal transduction and tumorigenesis |
| Q34178490 | Nerve growth factor signals via preexisting TrkA receptor oligomers |
| Q39141642 | PDGFRA alterations in cancer: characterization of a gain-of-function V536E transmembrane mutant as well as loss-of-function and passenger mutations |
| Q52075213 | Probing stability of helical transmembrane proteins. |
| Q33723925 | Receptor signaling: when dimerization is not enough |
| Q34525985 | Role of receptor tyrosine kinase transmembrane domains in cell signaling and human pathologies |
| Q34769307 | Rotational coupling of the transmembrane and kinase domains of the Neu receptor tyrosine kinase |
| Q37764644 | Single-spanning transmembrane domains in cell growth and cell-cell interactions: More than meets the eye? |
| Q28368986 | Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor |
| Q28198048 | Structural analysis of receptor tyrosine kinases |
| Q35925840 | Structure and function of the epidermal growth factor (EGF/ErbB) family of receptors |
| Q27640593 | Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab |
| Q42917676 | The effect of hydrophilic substitutions and anionic lipids upon the transverse positioning of the transmembrane helix of the ErbB2 (neu) protein incorporated into model membrane vesicles |
| Q33180948 | The platelet-derived growth factor beta receptor as a target of the bovine papillomavirus E5 protein |
| Q52860395 | The transmembrane domain of the DnaJ-like protein DjlA is a dimerisation domain. |
| Q36274097 | Transmembrane domain sequence requirements for activation of the p185c-neu receptor tyrosine kinase |
| Q36583016 | Transmembrane helix orientation influences membrane binding of the intracellular juxtamembrane domain in Neu receptor peptides |
| Q37704902 | Transmembrane helix-helix interactions involved in ErbB receptor signaling. |
| Q35919443 | Transmembrane peptides as inhibitors of ErbB receptor signaling |
Search more.